Drug Trial Radar · NCT03350386
Drug-drug Interaction Study of FYU-981 and Oxaprozin
Last checked: Nov 20, 2026Latest source record: Sep 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Nov 2, 2017
Primary completion
Dec 5, 2017
Study completion Dec 5, 2017
Sponsor
- Lead sponsor
- Mochida Pharmaceutical Company, Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Fuji Yakuhin Co., Ltd.
- First posted
- Nov 22, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- Male only, from 20 years, up to 35 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is an open-label, 2-period add-on study to assess the drug-drug interaction between FYU-981 and oxaprozin. The purpose of this study is to investigate the pharmacokinetics of each period in a single administration of FYU-981 and concomitant administration of FYU-981 with oxaprozin at steady -state in healthy volunteers.
Conditions
- Healthy
Interventions
FYU-981Drug
Single administration
OxaprozinDrug
Repeated administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics (Cmax: Maximum plasma concentration)Time frame: 48 hours
- Pharmacokinetics (Tmax: Time to reach the peak plasma concentration)Time frame: 48 hours
- Pharmacokinetics (T1/2: Elimination half-life of plasma concentration)Time frame: 48 hours
- Pharmacokinetics (AUC: Area under the plasma concentration-time curve)Time frame: 48 hours
- Pharmacokinetics (CLtot/F: Total clearance / Fraction of dose absorbed)Time frame: 48 hours
- Pharmacokinetics (kel: Elimination rate constant)Time frame: 48 hours
- Pharmacokinetics (Vd/F: Distribution volume / Fraction of dose absorbed)Time frame: 48 hours
- Pharmacokinetics (MRT: Mean residence time)Time frame: 48 hours
- Safety (Incidence of treatment-emergent adverse event)Time frame: 20 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
P-One Clinic
Hachiōji, Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.